Zuo Ankai, Gao Chengfei, Jia Qiufeng, Zhang Meirong, Fu Ting, Li Tieshan, Wang Lin
From the Department of Rehabilitation Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China.
Department of Cardiology, Qilu Hospital of Shandong University, Jinan, China.
Am J Phys Med Rehabil. 2025 Jul 1;104(7):613-621. doi: 10.1097/PHM.0000000000002677. Epub 2025 Jan 8.
This study aims to compare the efficacy of platelet-rich plasma and corticosteroids in treating plantar fasciitis, focusing on pain relief, foot function, and plantar fascia thickness to identify the optimal treatment approach.
A comprehensive search of medical databases was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, utilizing an extensive keyword strategy. Inclusion criteria encompassed prospective randomized controlled trials involving adult patients with plantar fasciitis treated with local platelet-rich plasma or corticosteroid injections, specifically assessing outcomes such as the visual analog scale, American Orthopedic Foot and Ankle Society scores, and plantar fascia thickness.
The meta-analysis included 24 randomized controlled trials with 1653 participants. Platelet-rich plasma injections yielded significantly better visual analog scale scores compared to corticosteroid injections at 3 mos ( P = 0.03) and 6 mos ( P < 0.001), with no significant differences at 1 mo ( P = 0.12) and 12 mos ( P = 0.08). American Orthopedic Foot and Ankle Society scores demonstrated that platelet-rich plasma was superior to corticosteroid at 3 ( P = 0.05), 6 ( P < 0.001), and 12 mos ( P < 0.001), with no significant differences at 1 mo ( P = 0.31). Regarding plantar fascia thickness, there were no significant differences between platelet-rich plasma and corticosteroid at 1-1.5 mos ( P = 0.18), 3 mos ( P = 0.64), and 6 mos ( P = 0.05).
Platelet-rich plasma injections offer superior pain control compared to corticosteroids in the medium term (3-6 mos) but not in the short term or at 1 yr.
本研究旨在比较富血小板血浆和皮质类固醇治疗足底筋膜炎的疗效，重点关注疼痛缓解、足部功能和足底筋膜厚度，以确定最佳治疗方法。
按照系统评价和Meta分析的首选报告项目指南，采用广泛的关键词策略，对医学数据库进行全面检索。纳入标准包括涉及成年足底筋膜炎患者接受局部富血小板血浆或皮质类固醇注射治疗的前瞻性随机对照试验，具体评估视觉模拟评分、美国矫形足踝协会评分和足底筋膜厚度等结果。
Meta分析纳入了24项随机对照试验，共1653名参与者。与皮质类固醇注射相比，富血小板血浆注射在3个月（P = 0.03）和6个月（P < 0.001）时视觉模拟评分显著更好，在1个月（P = 0.12）和12个月（P = 0.08）时无显著差异。美国矫形足踝协会评分显示，富血小板血浆在3个月（P = 0.05）、6个月（P < 0.001）和12个月（P < 0.001）时优于皮质类固醇，在1个月时无显著差异（P = 0.31）。关于足底筋膜厚度，富血小板血浆和皮质类固醇在1 - 1.5个月（P = 0.18）、3个月（P = 0.64）和6个月（P = 0.05）时无显著差异。
在中期（3 - 6个月），富血小板血浆注射在控制疼痛方面优于皮质类固醇，但在短期或1年时并非如此。
